Current Issue : October-December Volume : 2024 Issue Number : 4 Articles : 1 Articles
The moxifloxacin HCl formulation was examined using a variety of methodologies, including FTIR, DSC and a standard calibration curve. The findings revealed no new formations, mismatches, or the loss of any peak in the formulation, suggesting drug-polymer compatibility. The granules had good flow characteristics, with AR values ranging from 32.1°C to 36.3°C. The tablets' hardness, friability, weight fluctuation and thickness were all satisfactory. The tablets displayed satisfactory properties after compression, with hardness ranging from 6.045±0.53 to 7.201±0.73 kg/cm2 and friability and thickness ranging from 0.30±0.35-0.64±0.47 and 7.9±0.1-8±0.1, respectively. The weight fluctuation and medication content were likewise within permissible limits. The disintegration time indicated that the time necessary to break the tablet into smaller particles was likewise within the allowed limit. Batch F5 achieved the highest quantity of dug release during the specified time period (98.67±1.58), indicating formulation effectiveness. The drug release kinetics was also investigated, with the improved formulation F5 showing Korsmeyer-Peppas release. The manufactured tablets stability was carefully tested in accordance with the International Council for Harmonization (ICH) guidelines, which included exposing the tablets to an expedited stability study for 90 days. The results suggested that the product's quality did not change significantly over the testing period....
Loading....